ArticleReviews in urology2004
The future in advanced prostate cancer: take your partners or is the last dance for me?
Article in Reviews in urology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 2 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent therapeutic initiatives have improved quality of life and survival for patients with advanced prostate cancer. This review focuses predominantly on prostate cancer that has become refractory to standard androgen ablation treatment. Planned trials will answer further questions on the optimal use and sequencing of currently available hormonal agents, cytotoxic therapies, and radiolabeled nucleotides. Future therapeutic advances are likely to come in 2 areas: targeted therapies and response prediction. Molecular targeted agents will be most useful in combination with each other or with established systemic therapies. The selection of combinations will require the application of paradigms targeting key biochemical pathways and specific microenvironments in prostate cancer. Response prediction for individual patients may be assisted by either pretreatment or sequential molecular profiling, or sequential imaging, or biochemical studies that predicate outcome prior to or soon after treatment has been initiated. To bring these advances to the metastatic prostate cancer patient, a series of well-designed clinical trials is needed that integrates the lessons learned through laboratory, translational, and clinical studies in recent years.
Identifiers
16985929PMC1472936W43623559What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.